A management method for the statistical results of patient-specific quality assurance for intensity-modulated radiation therapy.
There are many reports concerning patient-specific quality assurance (QA) for intensity-modulated radiation therapy (IMRT). However, reports about the statistical results of QA are lacking. Management methods for the results of the QA are needed, even though we have the ESTRO group recommendation that a tolerance limit of 1.96 standard deviation (SD) be established in each institution. The purpose of this study was to establish a management method for determining the tolerance limit and to report the statistical results of patient-specific QA. From April 2006 to March 2015, five linacs in the National Cancer Center, Tokyo, Japan, were used to treat 1185 patients with IMRT. Patient-specific QA was performed using an ion chamber, films, and some detectors. To establish a management method for the results, differences between the measured and calculated doses in the ion chamber were analyzed for each linac, each phantom, and each treatment site. The overall mean dose difference was 0.5 ± 1.3%, and the mean dose difference in each linac was 0.6 ± 1.2%, 0.9 ± 1.3%, -0.4 ± 1.4%, -0.1 ± 1.2% and -0.1 ± 0.9%. The difference between linacs and between treatment sites was significant (P < 0.001 and 0.01, respectively). The proportion of the dose difference within ±3% was 97.7%, and that was improved from 2006 to 2014. The results of the patient-specific QA should be managed for each linac and each treatment site in order to decide the suitable tolerance limit. Reports of statistical results will be helped if a new tolerance limit and action level will be considered.
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Satoshi
S
Nakamura
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Hiroyuki
H
Okamoto
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Akihisa
A
Wakita
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Rei
R
Umezawa
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Kana
K
Takahashi
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Koji
K
Inaba
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Naoya
N
Murakami
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Toru
T
Kato
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Hiroshi
H
Igaki
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Yoshinori
Y
Ito
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Yoshihisa
Y
Abe
Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tsukiji 5-1-1, Tokyo, 104-0045, Japan.
Jun
J
Itami
D004307:Dose-Response Relationship, Radiation; D006801:Humans; D010315:Particle Accelerators / Q000592:standards; D011785:Quality Assurance, Health Care; D050397:Radiotherapy, Intensity-Modulated / Q000592:standards*; D013223:Statistics as Topic
IMRT; Ppatient-specific QA; management method; statistical analysis; tolerance limit